vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $92.9M, roughly 2.0× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 1.8%, a 23.2% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs 23.3%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 34.6%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CLMB vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $92.9M |
| Net Profit | $3.3M | $23.2M |
| Gross Margin | 14.5% | 78.7% |
| Operating Margin | 2.1% | 24.1% |
| Net Margin | 1.8% | 25.0% |
| Revenue YoY | 32.1% | 23.3% |
| Net Profit YoY | -9.5% | 17.3% |
| EPS (diluted) | $0.18 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $92.9M | ||
| Q3 25 | $161.3M | $67.5M | ||
| Q2 25 | $159.3M | $63.2M | ||
| Q1 25 | $138.0M | $52.6M | ||
| Q4 24 | $161.8M | $75.4M | ||
| Q3 24 | $119.3M | $57.9M | ||
| Q2 24 | $92.1M | $52.7M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $23.2M | ||
| Q3 25 | $4.7M | $5.1M | ||
| Q2 25 | $6.0M | $-553.0K | ||
| Q1 25 | $3.7M | $-11.2M | ||
| Q4 24 | $7.0M | $19.8M | ||
| Q3 24 | $5.5M | $-901.0K | ||
| Q2 24 | $3.4M | $-4.7M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 78.7% | ||
| Q3 25 | 15.9% | 73.5% | ||
| Q2 25 | 16.5% | 73.7% | ||
| Q1 25 | 16.9% | 69.0% | ||
| Q4 24 | 19.3% | 77.6% | ||
| Q3 24 | 20.3% | 71.9% | ||
| Q2 24 | 20.2% | 69.5% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 24.1% | ||
| Q3 25 | 4.3% | 5.1% | ||
| Q2 25 | 5.0% | -3.2% | ||
| Q1 25 | 3.5% | -24.3% | ||
| Q4 24 | 7.2% | 24.5% | ||
| Q3 24 | 7.1% | -4.3% | ||
| Q2 24 | 4.6% | -11.5% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 25.0% | ||
| Q3 25 | 2.9% | 7.5% | ||
| Q2 25 | 3.7% | -0.9% | ||
| Q1 25 | 2.7% | -21.4% | ||
| Q4 24 | 4.3% | 26.3% | ||
| Q3 24 | 4.6% | -1.6% | ||
| Q2 24 | 3.7% | -8.9% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.46 | ||
| Q3 25 | $1.02 | $0.10 | ||
| Q2 25 | $1.30 | $-0.01 | ||
| Q1 25 | $0.81 | $-0.23 | ||
| Q4 24 | $1.52 | $0.40 | ||
| Q3 24 | $1.19 | $-0.02 | ||
| Q2 24 | $0.75 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $354.6M |
| Total Assets | $458.8M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $137.5M | ||
| Q3 25 | $49.8M | $135.4M | ||
| Q2 25 | $28.6M | $116.9M | ||
| Q1 25 | $32.5M | $112.9M | ||
| Q4 24 | $29.8M | $116.2M | ||
| Q3 24 | $22.1M | $101.7M | ||
| Q2 24 | $48.4M | $102.5M |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $354.6M | ||
| Q3 25 | $109.3M | $321.9M | ||
| Q2 25 | $105.2M | $306.8M | ||
| Q1 25 | $95.6M | $295.5M | ||
| Q4 24 | $90.6M | $292.0M | ||
| Q3 24 | $87.7M | $257.5M | ||
| Q2 24 | $79.8M | $243.0M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $488.0M | ||
| Q3 25 | $376.1M | $453.3M | ||
| Q2 25 | $420.7M | $435.6M | ||
| Q1 25 | $370.1M | $424.6M | ||
| Q4 24 | $469.2M | $432.7M | ||
| Q3 24 | $371.9M | $390.4M | ||
| Q2 24 | $302.8M | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $15.0M | ||
| Q3 25 | $22.2M | $22.1M | ||
| Q2 25 | $-2.2M | $8.2M | ||
| Q1 25 | $8.5M | $6.6M | ||
| Q4 24 | $16.0M | $22.2M | ||
| Q3 24 | $-3.6M | $10.2M | ||
| Q2 24 | $7.3M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | 0.65× | ||
| Q3 25 | 4.73× | 4.35× | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | 1.12× | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
